Abstract
In this manuscript, we present data comparing the effects of carvedilol and metoprolol on in vivo and in vitro cardiac function in both diabetic and non‐diabetic human patients, as well as in a rat model of type 2 diabetes (Zucker Diabetic Fatty rats). Our data demonstrate that both carvedilol and metoprolol are able to improve the contractility of cardiac muscle from diabetic humans and rats, as well as preserving cardiac function in both models. Importantly, we saw no extra improvement in individuals or animals that received carvedilol over those who received metoprolol, suggesting that any improvement in health outcomes provided by carvedilol (as seen in the COMET study) are not derived from differences in the contractile function of the cardiac muscle.